ALPHARETTA, Ga., Jan. 26, 2016 /PRNewswire/ -- EndoChoice Holdings, Inc. (NYSE: GI) announced today that Mark Gilreath, Founder and Chief Executive Officer, and David Gill, Chief Financial Officer are scheduled to participate in three investor conferences in February 2016.



    Event:                                LEERINK Partners 5th Annual
                                          Global Healthcare Conference

    Format:                               Presentation and One-on-One
                                          Meetings

    Date:                                Thursday, February 11, 2016

    Time:                                11:35 a.m. ET

    Location:                            New York, NY

    Participant:                          David Gill, Chief Financial
                                          Officer


    Event:                                2016 RBC Capital Markets Global
                                          Healthcare Conference

    Format:                               Presentation and One-on-One
                                          Meetings

    Date:                                Wednesday, February 24, 2016

    Time:                                10:00 a.m. ET

    Location:                            New York, NY

    Participant:                          David Gill, Chief Financial
                                          Officer


    Event:                               2016 BTIG MedTech Conference

    Format:                              One-on-One Meetings Only

    Date:                                 Wednesday, February 24 -Friday,
                                          February 26, 2016

    Location:                            Snowbird, UT

    Participant:                          Mark Gilreath, Founder and Chief
                                          Executive Officer

Audio webcasts of the Company's presentations will be available by visiting the investor relations section of EndoChoice's web site at www.endochoice.com. Replays of the presentations will be available for 90 days.

About EndoChoice:
Based near Atlanta, Georgia, EndoChoice (NYSE: GI) is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 30 countries. The Company was founded in 2008 and has rapidly developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy System (Fuse®). EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc.

Company Contact:
David Gill, Chief Financial Officer
678-585-1040
david.gill@endochoice.com

Investor Contacts:
Nick Laudico or Zack Kubow
The Ruth Group
646-536-7030 / 7020
nlaudico@theruthgroup.com
zkubow@theruthgroup.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/endochoice-to-present-at-investor-conferences-in-february-2016-300209247.html

SOURCE EndoChoice